Please ensure Javascript is enabled for purposes of website accessibility

Co-Diagnostics: Buy the Dip?

By Cory Renauer - Updated Mar 29, 2021 at 4:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Analysts following this coronavirus stock have darkened their post-pandemic outlook.

Co-Diagnostics (CODX 10.66%) was one of the best-performing stocks of 2020, but a fourth-quarter earnings report failed to impress investment banks that follow the molecular diagnostics company. The stock has been under pressure since Maxim downgraded the stock to hold, and H.C. Wainwright cut its price target on Co-Diagnostics by nearly half.

Is Co-Diagnostics a good stock to buy on the dip, or should you remain cautious?

Investor pondering in front of her computer.

Image source: Getty Images.

The most important thing to remember about this company is that it currently relies on COVID-19 testing for nearly all revenue. Unfortunately, cash flows from coronavirus testing have probably peaked.

Despite having access to public markets since its initial public offering (IPO) in 2017, last year was the first time that Co-Diagnostics was able to report an annual profit. After earning around $42 million in 2020, expectations for 2021 are significantly lower, and there isn't another hit diagnostic test ready to take over.

Although it gave up around 40% of its value over the past week, Co-Diagnostics still boasts a $250 million market cap at recent prices. That's an awful lot to pay for a company without a significant revenue source to lean on once the demand for COVID-19 tests falls off a cliff. 

Co-Diagnostics' proprietary technology platform is positioned to play a big role in the market for molecular diagnostics, but this is a hypercompetitive industry. It's probably best to wait and see if this company can achieve post-pandemic profitability before adding this risky stock to your portfolio.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
CODX
$5.50 (10.66%) $0.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.